IL1B and neoplasm: Given the increase in production of IL‐1β, TNF‐α, IL‐12, IL‐22, and IL‐6 by the expanded inflammatory Ly6C+MHCII+ monocyte population in the tumor following the administration of SL7207, it was hypothesized that monocyte populations may underpin the tumor‐growth inhibition effects of SL7207.